NSE:ERIS (India)
Â
Registered Shs
₹
1,382.9
-0.10 (-0.01%)
Apr 21
What is a stock summary page? Click here for an overview.
Business Description
Eris Lifesciences Ltd
ISIN : INE406M01024
Share Class Description:
NSE:ERIS: Registered ShsCompare
Compare
Traded in other countries / regions
540596.India Index Membership
NIFTY 500 IPO Date
2017-06-29Description
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.09 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 0.99 | |||||
| Debt-to-EBITDA | 2.91 | |||||
| Interest Coverage | 2.97 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.65 | |||||
| Beneish M-Score | -2.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 18.6 | |||||
| 3-Year EBITDA Growth Rate | 16.6 | |||||
| 3-Year EPS without NRI Growth Rate | 3.2 | |||||
| 3-Year FCF Growth Rate | 0.6 | |||||
| 3-Year Book Growth Rate | 17.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 26.44 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 23.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.36 | |||||
| 9-Day RSI | 56.91 | |||||
| 14-Day RSI | 56.54 | |||||
| 3-1 Month Momentum % | 9.84 | |||||
| 6-1 Month Momentum % | 4.75 | |||||
| 12-1 Month Momentum % | 58.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.07 | |||||
| Quick Ratio | 0.86 | |||||
| Cash Ratio | 0.2 | |||||
| Days Inventory | 106.2 | |||||
| Days Sales Outstanding | 56.27 | |||||
| Days Payable | 127.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.53 | |||||
| Forward Dividend Yield % | 1.06 | |||||
| 5-Year Yield-on-Cost % | 0.53 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | -9.59 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.42 | |||||
| Operating Margin % | 22.94 | |||||
| Net Margin % | 12.09 | |||||
| FCF Margin % | 13.1 | |||||
| ROE % | 12.72 | |||||
| ROA % | 5.51 | |||||
| ROIC % | 8.84 | |||||
| 3-Year ROIIC % | 1.99 | |||||
| ROC (Joel Greenblatt) % | 46.34 | |||||
| ROCE % | 14.19 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 57.2 | |||||
| Forward PE Ratio | 34.47 | |||||
| PE Ratio without NRI | 57.2 | |||||
| Shiller PE Ratio | 54.06 | |||||
| Price-to-Owner-Earnings | 71.46 | |||||
| PEG Ratio | 4.27 | |||||
| PS Ratio | 6.92 | |||||
| PB Ratio | 6.79 | |||||
| Price-to-Free-Cash-Flow | 52.78 | |||||
| Price-to-Operating-Cash-Flow | 38.75 | |||||
| EV-to-EBIT | 33.57 | |||||
| EV-to-Forward-EBIT | 16.73 | |||||
| EV-to-EBITDA | 23.14 | |||||
| EV-to-Forward-EBITDA | 17.59 | |||||
| EV-to-Revenue | 7.98 | |||||
| EV-to-Forward-Revenue | 6.17 | |||||
| EV-to-FCF | 60.89 | |||||
| Price-to-GF-Value | 0.92 | |||||
| Price-to-Projected-FCF | 4.66 | |||||
| Price-to-DCF (Earnings Based) | 2.36 | |||||
| Price-to-DCF (FCF Based) | 5.3 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.16 | |||||
| Earnings Yield (Greenblatt) % | 2.98 | |||||
| FCF Yield % | 1.89 | |||||
| Forward Rate of Return (Yacktman) % | 18.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eris Lifesciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 27,239.25 | ||
| EPS (TTM) (₹) | 24.18 | ||
| Beta | 0.62 | ||
| 3-Year Sharpe Ratio | 0.77 | ||
| 3-Year Sortino Ratio | 1.55 | ||
| Volatility % | 32.38 | ||
| 14-Day RSI | 56.54 | ||
| 14-Day ATR (₹) | 69.220812 | ||
| 20-Day SMA (₹) | 1364.615 | ||
| 12-1 Month Momentum % | 58.94 | ||
| 52-Week Range (₹) | 815.85 - 1593.9 | ||
| Shares Outstanding (Mil) | 136.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eris Lifesciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eris Lifesciences Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eris Lifesciences Ltd Frequently Asked Questions
What is Eris Lifesciences Ltd(NSE:ERIS)'s stock price today?
The current price of NSE:ERIS is ₹1382.90. The 52 week high of NSE:ERIS is ₹1593.90 and 52 week low is ₹815.85.
When is next earnings date of Eris Lifesciences Ltd(NSE:ERIS)?
The next earnings date of Eris Lifesciences Ltd(NSE:ERIS) is 2025-05-21 Est..
Does Eris Lifesciences Ltd(NSE:ERIS) pay dividends? If so, how much?
The Dividend Yield %  of Eris Lifesciences Ltd(NSE:ERIS) is 0.53% (As of Today), Highest Dividend Payout Ratio of Eris Lifesciences Ltd(NSE:ERIS) was 0.27. The lowest was 0.14. And the median was 0.21. The  Forward Dividend Yield % of Eris Lifesciences Ltd(NSE:ERIS) is 1.06%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers